Policy & Regulation
X-Chem and Relay Therapeutics collaborate on Phase 3 milestone
23 September 2026 - X-Chem, a US-based global company involved in innovative drug discovery services, announced on Tuesday the achievement of a milestone following Relay Therapeutics' initiation ...
BoomRay enters exclusive radioligand therapy asset global license agreement with Novartis
23 September 2026 - BoomRay Pharmaceuticals Co., Ltd., a China-based clinical-stage biotechnology company involved in innovative radioligand therapies (RLTs) for precision oncology diagnostics and the...
AstronauTx receives funding to explore sleep-based approaches for Parkinson's disease
23 September 2026 - AstronauTx Ltd, a UK-based biotechnology company, announced on Tuesday that it has received funding from The Michael J. Fox Foundation for Parkinson's Research (MJFF), and tha...
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis
22 September 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) said on Tuesday it has received European Commission approval for RINVOQ (upadacitinib) to treat active polyarticular juvenile idiop...
Genentech reports positive Phase II results for enicepatide in type 2 diabetes
22 September 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), on Tuesday reported positive topline Phase II results for enicepatide, an investigationa...
Pharming reports positive Phase II data for leniolisib in primary immunodeficiencies
22 September 2026 - Biopharmaceutical company Pharming Group N.V. (Euronext Amsterdam:PHARM) (NASDAQ:PHAR) on Tuesday announced positive topline Phase II data for leniolisib in genetically identifiabl...